文献速递胸部肿瘤放疗

碳离子放射治疗不可手术I期非小细胞肺癌的临床结果:日本全国登记研究(J-CROS-LUNG)

Clinical results of carbon ion radiotherapy for inoperable stage I non-small cell lung cancer: A Japanese national registry study (J-CROS-LUNG).
PubMed 文献 · Radiother Oncol · 2023-03-27

该研究为日本全国前瞻性登记研究,纳入2016年5月至2018年6月间95例接受碳离子放射治疗的不可手术I期非小细胞肺癌患者。3年总生存率、病因特异性生存率和局部控制率分别为59.3%、77.1%和87.3%,未观察到4级及以上不良事件,2级及以上放射性肺炎3年累积发生率为3.2%。

要点

  • 碳离子放射治疗不可手术I期NSCLC的3年总生存率为59.3%,局部控制率为87.3%。
  • 女性及ECOG体力状态评分0-1为总生存的有利预后因素。
  • 2级及以上放射性肺炎3年累积发生率为3.2%,风险因素为FEV1<0.9 L和总剂量≥67 Gy(RBE)。

核心结论

  • 本研究提供了日本碳离子放射治疗不可手术I期非小细胞肺癌的真实世界治疗结果。

研究设计与样本

  • 日本全国前瞻性登记研究,纳入2016年5月至2018年6月间接受碳离子放射治疗的95例不可手术I期非小细胞肺癌患者。
  • 碳离子放射治疗的剂量分割方案从日本放射肿瘤学会批准的若干选项中选取。

主要发现

  • 患者中位年龄77岁,慢性阻塞性肺疾病合并率为43%,间质性肺炎合并率为26%。
  • 最常见的碳离子放射治疗方案为60 Gy(RBE)分4次,其次为50 Gy(RBE)分1次。
  • 3年总生存率、病因特异性生存率和局部控制率分别为59.3%、77.1%和87.3%。
  • 多因素分析显示女性和ECOG体力状态评分0-1为总生存的有利预后因素。
  • 未观察到4级及以上不良事件,2级及以上放射性肺炎3年累积发生率为3.2%;其风险因素为第1秒用力呼气容积<0.9 L和总剂量≥67 Gy(RBE)。

关键数值与推荐

  • 3年总生存率59.3%,病因特异性生存率77.1%,局部控制率87.3%。
  • 2级及以上放射性肺炎3年累积发生率为3.2%。
  • 2级及以上放射性肺炎风险因素:第1秒用力呼气容积<0.9 L和总剂量≥67 Gy(RBE)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiotherapy is a standard treatment for inoperable stage I non-small cell lung cancer (NSCLC), and carbon-ion radiation therapy (CIRT) may be used for such treatment. Although CIRT for stage I NSCLC has demonstrated favorable outcomes in previous reports, the reports covered only single-institution studies. We conducted a prospective nationwide registry study including all CIRT institutions in Japan. MATERIALS AND METHODS: Ninety-five patients with inoperable stage I NSCLC were treated by CIRT between May 2016 and June 2018. The dose fractionations for CIRT were selected from several options approved by the Japanese Society for Radiation Oncology. RESULTS: The median patient age was 77 years. Comorbidity rates for chronic obstructive pulmonary disease and interstitial pneumonia were 43% and 26%, respectively. The most common schedule for CIRT was 60 Gy (relative biological effectiveness (RBE)) in four fractions, and the second most common was 50 Gy (RBE) in one fraction. The 3-year overall survival, cause-specific survival, and local control rates were 59.3%, 77.1%, and 87.3%, respectively. Female sex and ECOG performance status of 0-1 were favorable prognostic factors for overall survival in a multivariate analysis. No grade 4 or higher adverse event was observed. The 3-year cumulative incidence of grade 2 or higher radiation pneumonitis was 3.2%. The risk factors for grade 2 or higher radiation pneumonitis were a force expiratory volume in 1 second (FEV1) of <0.9 L and a total does of ≥ 67 Gy(RBE). CONCLUSION: This study provides real-world treatment outcomes of CIRT for inoperable. stage I NSCLC in Japan.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kubo N, Suefuji H, Nakajima M, et al. Clinical results of carbon ion radiotherapy for inoperable stage I non-small cell lung cancer: A Japanese national registry study (J-CROS-LUNG). Radiother Oncol. 2023. PMID: 36990390. doi:10.1016/j.radonc.2023.109640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。